TheraRadar
← Back
Data updated: Jun 28, 2026

CORCEPT THERAP

Pharma
OncologyMetabolicInfectious Disease Execution: Good

CORCEPT THERAP is a pharmaceutical company focused on Oncology, Metabolic, Infectious Disease. Key products include KORLYM.

2012
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
2 Small Molecules

CORCEPT THERAP at a Glance

  • Fast trial execution (9 months median completion)

Upcoming FDA Decisions

Full Calendar →
Jul 11, 2026 — Relacorilant + nab-paclitaxel
0d

CORCEPT THERAP's Key Drugs

CORCEPT THERAP's core commercial portfolio centers on KORLYM, LIFYORLI (COPACKAGED), spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.

KORLYM
Metabolic

Hyperglycemia

Glucocorticoid receptor Approved 2012
LIFYORLI (COPACKAGED)
Approved 2026

CORCEPT THERAP's Recent FDA Approvals

CORCEPT THERAP secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

LIFYORLI (COPACKAGED) NDA
2026-03-25
relacorilant
1 INDICATIONS AND USAGE LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )] . LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. ( 1 , 14 )

CORCEPT THERAP's Therapeutic Areas

CORCEPT THERAP's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 48%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 6
Metabolic 26%
1 drugs Phase 2: 1 Phase 1: 3
Infectious Disease 21%
0 drugs Phase 2: 2 Phase 1: 5
Gastroenterology 5%
0 drugs Phase 1: 2

CORCEPT THERAP's Top Competitors

CORCEPT THERAP's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Infectious Disease, Gastroenterology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Baxter specialty
Infectious Disease, Oncology, Metabolic
ASTELLAS specialty
Oncology, Metabolic, Gastroenterology, Infectious Disease
GSK big-pharma
Infectious Disease, Oncology, Metabolic

CORCEPT THERAP Pipeline Snapshot

CORCEPT THERAP has 24 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 6 Phase 2 and 16 Phase 1.

2
Phase 3
6
Phase 2
16
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • KORLYM leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/8 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges